The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Mutational profiling reveals subset of R/R AML that may benefit from quizartinib
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, explains the effect of co-mutations and FLT3-ITD variant allele frequency on response to quizartinib or salvage chemotherapy in relapsed/refractory acute myeloid leukemia (R/R AML), using data from the QuANTUM-R trial (NCT02039726). In particular, the results of the anslysis performed indicated that a specific subset of R/R AML patients may benefit from quizartinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
